PAN-CLO-BU (PANcreas-CLOstridium-BUtyricum)

This is a prospective, randomized, double-blind, single-center clinical trial designed to evaluate the effects of Clostridium butyricum CBM588 supplementation on postoperative diarrhea, gastrointestinal symptoms, and quality of life in patients undergoing pancreaticoduodenectomy for periampullary neoplasms. Oncological outcomes, including disease-free survival and overall survival, will be monitored as secondary endpoints during follow-up.

NCT Number	NCT07422103
Lead Sponsor	Casa di Cura Dott. Pederzoli Collaborators: PharmExtracta S.p.A.
Conditions	Pancreatic Cancer, Pancreatic Diseases, Gastrointestinal Symptoms, Clostridium Butyricum Miyairi, Pancreatoduodenectomy, CBM588
Enrollment	158 participants
Start Date	2026-03-15
Primary Completion	2028-11-30 (estimated)
Study Completion	2030-11-30 (estimated)
Updated on ClinicalTrials.gov	2026-02-19